New t cell engager takes on tough colorectal cancer
NCT ID NCT07321106
First seen Jan 07, 2026 · Last updated Jun 22, 2026 · Updated 28 times
Summary
This early-phase trial tests a new drug called CBI-1214 in 80 people with advanced colorectal cancer that has not responded to standard treatments. CBI-1214 is designed to connect the body's own immune T cells to cancer cells, helping the immune system attack the tumor. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Duarte
RECRUITINGDuarte, California, 91010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Emory Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UCLA
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCSF
RECRUITINGSan Francisco, California, 94158, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Valkyrie Clinical Trials
RECRUITINGLos Angeles, California, 91402, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CBI-1214 (a T cell engager that links immune cells to cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for advanced colorectal cancer that is hard to treat with current therapies.
What could go wrong
This is a very early, first-in-human trial with only 80 participants. The drug may not shrink tumors or could cause significant side effects. Many early-stage cancer drugs do not advance to later trials.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.